Response to doxorubicin and cyclophosphamide of a human pleural mesothelioma clinically and as a xenograft in nude rats.
The effect of doxorubicin (DOX) and cyclophosphamide (CYC) on human pleural mesothelioma AKG was evaluated clinically and compared to the response of the same tumour as a xenograft in athymic rats. The response of the xenograft to each of the drugs was assessed as reduction of the area under the tumour--volume curve (1-AUC), as reduction of the relative tumour volume (1-RTV) and as specific growth delay (SGD) induced by the drug. Treatment of the xenograft with DOX (7mg/kg i.p.) as a single drug at the maximum tolerated dose (MTD) in athymic rats resulted in 1-AUC, 1-RTV and SGD of 0.54, 0.44 and 0.77, respectively. Likewise, treatment with CYC (100 mg/kg i.p.) at MTD resulted in 1-AUC, 1-RTV and SGD of 0.72, 0.45 and 0.73, respectively. Drugs were denoted as active if 1-AUC greater than 0.85, 1-RTV greater than 0.64 or SGD greater than 2. Consequently, both drugs were classified as inactive against the xenograft, corresponding to the progression of the patient's tumour during treatment with a combination of DOX and CYC at MTD.
Lindén
C J
CJ
Department of Lung Medicine, University Hospital, Lund, Sweden.
D000818:Animals; D002460:Cell Line; D003520:Cyclophosphamide / Q000627:therapeutic use* / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy* / Q000473:pathology; D009368:Neoplasm Transplantation; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D011923:Rats, Nude; D014183:Transplantation, Heterologous
D004317:Doxorubicin; D003520:Cyclophosphamide